Au Nanoparticles Anchored on Cobalt Boride Nanowire Arrays for the Electrochemical Determination of Prostate-Specific Antigen

Author(s):  
Cancan Bao ◽  
Rui Zhang ◽  
Yanxia Qiao ◽  
Xiaowei Cao ◽  
Fangyuan He ◽  
...  
2012 ◽  
Vol 4 (6) ◽  
pp. 1725 ◽  
Author(s):  
Juan Li ◽  
Juan Yang ◽  
Zhanjun Yang ◽  
Yongfang Li ◽  
Suhua Yu ◽  
...  

2019 ◽  
Vol 11 (37) ◽  
pp. 4751-4760 ◽  
Author(s):  
Xu-Cheng Fu ◽  
Chao Zhang ◽  
Xuan-Hua Li ◽  
Jian Zhang ◽  
Gan Wei

In this work, two-dimensional TiO2 nanosheets material composited with Au nanoparticles and mono-6-thio-β-cyclodextrin was prepared on electrode surface (SH-β-CD/AuNPs/TiO2NSs/GCE).


2015 ◽  
Vol 7 (4) ◽  
pp. 1471-1477 ◽  
Author(s):  
Siyuan Wang ◽  
Wen Zhang ◽  
Xia Zhong ◽  
Yaqin Chai ◽  
Ruo Yuan

A nanohybrid (RGO–PAMAM–MWCNT–AuNPs) for simultaneous electrochemical determination of ascorbic acid (AA), dopamine (DA) and uric acid (UA) was reported in this paper.


2003 ◽  
Vol 49 (6) ◽  
pp. 887-894 ◽  
Author(s):  
Sebastian Wesseling ◽  
Carsten Stephan ◽  
Axel Semjonow ◽  
Michael Lein ◽  
Brigitte Brux ◽  
...  

Abstract Background: A new assay measures prostate-specific antigen (PSA) not complexed to α1-antichymotrypsin (nACT-PSA) after removing PSA complexed to ACT by use of anti-ACT antibodies. We evaluated nACT-PSA and its ratio to total PSA (tPSA) as alternatives to free PSA (fPSA) and its ratio to tPSA in differentiating prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in patients with tPSA of 2–20 μg/L. Methods: PSA in serum of 183 untreated patients with PCa and 132 patients with BPH was measured retrospectively on the chemiluminescence immunoassay analyzer LIAISON® (Byk-Sangtec Diagnostica) with the LIAISON tPSA and LIAISON fPSA assays. The nACT-PSA fraction was determined with a prototype assay measuring the residual PSA after precipitation of ACT-PSA with an ACT-precipitating reagent. Results:nACT-PSA was higher than fPSA in samples with fPSA concentrations <1 μg/L but lower in samples with >1 μg/L fPSA. The median ratios of fPSA/tPSA and of nACT-PSA/tPSA were significantly different between patients with BPH and PCa (19.4% vs 12.2% and 17.4% vs 13.0%, respectively). Within the tPSA ranges tested (2–20, 2–10, and 4–10 μg/L), areas under the ROC curves for the fPSA/tPSA ratios were significantly larger than those for nACT-PSA/tPSA. In the tPSA ranges <10 μg/L, the areas under the ROC curves for fPSA/tPSA were significantly larger than those for tPSA, whereas the areas for nACT-PSA/tPSA were not. At decision limits for 95% sensitivity and specificity, both ratios significantly increased specificity and sensitivity, respectively, compared with tPSA, but the fPSA/tPSA ratio showed higher values. Conclusions: nACT-PSA and its ratio to tPSA provide lower diagnostic sensitivity and specificity than fPSA/tPSA. The fPSA/tPSA ratio represents the state-of-the-art method for differentiating between PCa and BPH.


Sign in / Sign up

Export Citation Format

Share Document